{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:05:49Z","timestamp":1775300749894,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>For 2 decades, U.S. combat casualty care relied on rapid evacuation, effectively outsourcing late-stage coagulopathy management to resource-laden specialists at Role 3 facilities and above. As we pivot to Large-Scale Combat Operations (LSCO) and the realities of Prolonged Casualty Care (PCC), this paradigm is no longer reliable. Our Austere Resuscitative Surgical Care (ARSC) assets, such as Forward Resuscitative and Surgical Detachments (FRSDs), will hold critically ill casualties for 24 hours or longer, making them responsible for managing the predictable, hypofibrinogenemic dilutional coagulopathy that occurs deep into massive transfusion protocols (MTP)\u2014a condition for which their standard equipment sets lack the optimal treatment. This commentary argues for equipping ARSC assets with Fibrinogen Concentrate (FC) and proposes a pragmatic, evidence-based framework for its administration when advanced diagnostics are unavailable. The argument rests on 3 pillars. First, FC is clinically non-inferior to cryoprecipitate for treating acquired hypofibrinogenemia, as established by the FIBRES trial and confirmed by systematic reviews, while being logistically superior in every dimension critical to austere care: room-temperature storage, rapid reconstitution, standardized dosing, and a minimal logistical footprint. Second, the historical barriers to adoption\u2014regulatory and safety concerns\u2014have been eliminated by the 2024 FDA approval of FC for acquired fibrinogen deficiency and by large trials demonstrating no increased thromboembolic risk. Third, a synthesis of military blood-planning data with contemporary civilian transfusion research\u2014including the largest analysis to date, nearly 50,000 massively transfused patients\u2014demonstrates that a significant majority of combat surgical casualties will reach the transfusion volume threshold where fibrinogen supplementation is indicated, making FC a standard hemostatic tool rather than a niche rescue therapy. Standard MTPs already include cryoprecipitate in the second and subsequent batches at the Role 3. This commentary does not advocate for early empiric fibrinogen supplementation\u2014a strategy recently tested in randomized trials that failed to demonstrate mortality benefit. It argues instead, in massively transfused patients who cannot be evacuated, to substitute the Role 3\u2019s threshold-triggered cryoprecipitate delivery with FC at ARSC platforms where cryoprecipitate is physically unavailable. This commentary proposes that FC administration in austere settings be guided by the standards that exist at the Role 3: transfusion volume triggers, validated clinical indicators of hypofibrinogenemia, and viscoelastic testing when available. FC warrants inclusion in the medical equipment sets for all ARSC assets to close a lethal capabilities gap.<\/jats:p>","DOI":"10.1093\/milmed\/usag144","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T12:40:02Z","timestamp":1773578402000},"source":"Crossref","is-referenced-by-count":0,"title":["The Second Battle: Equipping Austere Surgical Teams for Post-Resuscitation Coagulopathy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6238-5506","authenticated-orcid":false,"given":"Jonathan L","family":"Custer","sequence":"first","affiliation":[{"name":"Department of Anesthesia, Madigan Army Medical Center , 124th Forward Resuscitative Surgical Detachment, 9040a Jackson Ave , JBLM, WA, 98439,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J","family":"Bedard","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Madigan Army Medical Center, 124th Forward Resuscitative Surgical Detachment , 9040a Jackson Ave , JBLM, WA, 98439,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"2026040406075804100_usag144-B1","doi-asserted-by":"publisher","first-page":"S431","DOI":"10.1097\/TA.0b013e3182755dcc","article-title":"Death on the battlefield (2001\u20132011). Death on the battlefield (2001-2011): implications for the future of combat casualty care","volume":"73","author":"Eastridge","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"key":"2026040406075804100_usag144-B2","author":"Joint Trauma System","year":"2021"},{"key":"2026040406075804100_usag144-B3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/TA.0b013e3181877a9c","article-title":"The coagulopathy of trauma: a review of mechanisms","volume":"65","author":"Hess","year":"2008","journal-title":"J Trauma"},{"key":"2026040406075804100_usag144-B4","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1097\/TA.0b013e318160a57b","article-title":"The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital","volume":"64","author":"Stinger","year":"2008","journal-title":"J Trauma"},{"key":"2026040406075804100_usag144-B5","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1111\/trf.17774","article-title":"Analyzing and modeling massive transfusion strategies and the role of fibrinogen\u2014how much is the patient actually receiving?","volume":"64","author":"Keltner","year":"2024","journal-title":"Transfusion"},{"key":"2026040406075804100_usag144-B6","doi-asserted-by":"publisher","first-page":"e001674","DOI":"10.1136\/tsaco-2024-001674","article-title":"Qualitative assessment of point of injury to role 2+ combat casualty care in Ukraine","volume":"10","author":"Lawry","year":"2025","journal-title":"Trauma Surg Acute Care Open"},{"key":"2026040406075804100_usag144-B7","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1097\/TA.0000000000003628","article-title":"US Central command military blood utilization practices 2011 to 2020","volume":"93","author":"Hall","year":"2022","journal-title":"J Trauma Acute Care Surg"},{"key":"2026040406075804100_usag144-B8","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1097\/TA.0000000000004413","article-title":"The thin red line: blood planning factors and the enduring need for a robust military blood system to support combat operations","volume":"97","author":"Gurney","year":"2024","journal-title":"J Trauma Acute Care Surg"},{"key":"2026040406075804100_usag144-B9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/TA.0000000000004643","article-title":"Where does cryoprecipitate fit into balanced resuscitation? An evaluation of 2,117 hemorrhaging patients using viscoelastic-based resuscitation","volume":"99","author":"Van Gent","year":"2025","journal-title":"J Trauma Acute Care Surg"},{"key":"2026040406075804100_usag144-B10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/TA.0000000000004862","article-title":"Do not forget the cryoprecipitate: the impact of the 2019 joint trauma system damage control resuscitation clinical practice guideline on mortality","volume":"100","author":"Hynes","year":"2026","journal-title":"J Trauma Acute Care Surg"},{"key":"2026040406075804100_usag144-B11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/TA.0000000000004060","article-title":"Optimal dose of cryoprecipitate in massive transfusion following trauma","volume":"96","author":"Dorken-Gallastegi","year":"2024","journal-title":"J Trauma Acute Care Surg"},{"key":"2026040406075804100_usag144-B12","author":"Joint Trauma System","year":"2019"},{"key":"2026040406075804100_usag144-B13","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/jama.2023.21019","article-title":"Early and empirical high-dose cryoprecipitate for hemorrhage after traumatic injury: the CRYOSTAT-2 randomized clinical trial","volume":"330","author":"Davenport","year":"2023","journal-title":"JAMA"},{"key":"2026040406075804100_usag144-B14","doi-asserted-by":"publisher","first-page":"e2532702","DOI":"10.1001\/jamanetworkopen.2025.32702","article-title":"Factors in the initial resuscitation of patients with severe trauma: the FiiRST-2 randomized clinical trial","volume":"8","author":"da Luz","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026040406075804100_usag144-B15","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1001\/jama.2019.17312","article-title":"Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial","volume":"322","author":"Callum","year":"2019","journal-title":"JAMA"},{"key":"2026040406075804100_usag144-B16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.51893\/2021.1.OA3","article-title":"Fibrinogen Early In Severe Trauma studY (FEISTY): results from an Australian multicentre randomised controlled pilot trial","volume":"23","author":"Winearls","year":"2021","journal-title":"Crit Care Resusc."},{"key":"2026040406075804100_usag144-B17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/TA.0000000000003728","article-title":"Fibrinogen supplementation for the trauma patient: should you choose fibrinogen concentrate over cryoprecipitate?","volume":"93","author":"Obaid","year":"2022","journal-title":"J Trauma Acute Care Surg"},{"key":"2026040406075804100_usag144-B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13054-025-05269-y","article-title":"Effect of early administration of fibrinogen replacement therapy in traumatic haemorrhage: a systematic review and meta-analysis of randomised controlled trials with narrative synthesis of observational studies","volume":"29","author":"Burt","year":"2025","journal-title":"Crit Care."},{"key":"2026040406075804100_usag144-B19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tmrv.2021.06.005","article-title":"Fibrinogen replacement in haemostatic resuscitation: dose, laboratory targets and product choice","volume":"35","author":"Curry","year":"2021","journal-title":"Transfus Med Rev."},{"key":"2026040406075804100_usag144-B20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/jamasurg.2022.6818","article-title":"Cost-effectiveness of fibrinogen concentrate vs cryoprecipitate for treating acquired hypofibrinogenemia in bleeding adult cardiac surgical patients","volume":"158","author":"Abrahamyan","year":"2023","journal-title":"JAMA Surg"},{"key":"2026040406075804100_usag144-B21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-015-0310-1","article-title":"Malignant hyperthermia: a review","volume":"10","author":"Rosenberg","year":"2015","journal-title":"Orphanet J Rare Dis."},{"key":"2026040406075804100_usag144-B22","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/milmed\/usx057","article-title":"Fibrinogen concentrate in the Special Operations Forces environment","volume":"183","author":"Sanders","year":"2018","journal-title":"Mil Med."},{"key":"2026040406075804100_usag144-B23","author":"Agency for Clinical Innovation. Fibrinogen administration in prehospital trauma. NSW Government; 2022"},{"key":"2026040406075804100_usag144-B24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s44158-025-00248-9","article-title":"Blood product administration in the prehospital setting: a multisociety consensus statement","volume":"5","author":"Carenzo","year":"2025","journal-title":"J Anesth Analg Crit Care."},{"issue":"1","key":"2026040406075804100_usag144-B25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13054-023-04327-7","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition","volume":"27","author":"Rossaint","year":"2023","journal-title":"Crit Care."},{"key":"2026040406075804100_usag144-B26","doi-asserted-by":"publisher","first-page":"CD010649","DOI":"10.1002\/14651858.CD010649.pub2","article-title":"Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia","volume":"12","author":"Fabes","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"2026040406075804100_usag144-B27","first-page":"2024","article-title":"FDA approves fibryga for acquired fibrinogen deficiency, potentially ushering in a new standard of care","volume":"8","author":"Octapharma","journal-title":"Press release. September"},{"key":"2026040406075804100_usag144-B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.medine.2025.502296","article-title":"Early identification of hypofibrinogenemia in major trauma: the usefulness of the FiT-6 (Fibrinogen in Trauma-6) score","volume":"49","author":"Ruiz-Bocos","year":"2025","journal-title":"Med Intensiva (Engl Ed)"},{"key":"2026040406075804100_usag144-B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/EJA.0000000000000734","article-title":"Fibrinogen on admission in trauma score: early prediction of low plasma fibrinogen concentrations in trauma patients","volume":"35","author":"Gauss","year":"2018","journal-title":"Eur J Anaesthesiol."},{"key":"2026040406075804100_usag144-B30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/emermed-2023-213844","article-title":"Comparison between point-of-care international normalised ratio, COAST, TICCS and truncated FibAT scores to rule in clinically significant hypofibrinogenaemia in the prehospital setting","volume":"42","author":"Bodnar","year":"2025","journal-title":"Emerg Med J."},{"key":"2026040406075804100_usag144-B31","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/trf.12431","article-title":"Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy","volume":"54","author":"Levy","year":"2014","journal-title":"Transfusion."},{"key":"2026040406075804100_usag144-B32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJMra1208626","article-title":"Bleeding and coagulopathies in critical care","volume":"370","author":"Hunt","year":"2014","journal-title":"N Engl J Med."},{"key":"2026040406075804100_usag144-B33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1309\/NQXH-UG7H-ND78-LFFK","article-title":"Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results","volume":"126","author":"Holland","year":"2006","journal-title":"Am J Clin Pathol."},{"key":"2026040406075804100_usag144-B34","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1213\/ANE.0000000000004315","article-title":"Viscoelastic signals for optimal resuscitation in trauma: Kaolin thrombelastography cutoffs for diagnosing hypofibrinogenemia (VISOR Study)","volume":"129","author":"Chow","year":"2019","journal-title":"Anesth Analg."},{"key":"2026040406075804100_usag144-B35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/TA.0000000000002634","article-title":"Viscoelastic testing in combat resuscitation: is it time for a new standard?","volume":"89","author":"Lammers","year":"2020","journal-title":"J Trauma Acute Care Surg"},{"key":"2026040406075804100_usag144-B36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm11020356","article-title":"Hemorrhagic resuscitation guided by viscoelastography in far-forward combat and austere civilian environments: goal-directed whole-blood and blood-component therapy far from the trauma center","volume":"11","author":"Lantry","year":"2022","journal-title":"J Clin Med."}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/advance-article-pdf\/doi\/10.1093\/milmed\/usag144\/67783831\/usag144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/advance-article-pdf\/doi\/10.1093\/milmed\/usag144\/67783831\/usag144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:08:02Z","timestamp":1775297282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/advance-article\/doi\/10.1093\/milmed\/usag144\/8586512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":36,"URL":"https:\/\/doi.org\/10.1093\/milmed\/usag144","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"article-number":"usag144"}}